Faculty Collaboration Database

Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. J Natl Cancer Inst 2023 Jul 06;115(7):831-837

Date

04/19/2023

Pubmed ID

37074956

Pubmed Central ID

PMC10323894

DOI

10.1093/jnci/djad070

Scopus ID

2-s2.0-85159271658 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of ovarian cancer; however, real-world data on kidney function among patients treated with PARPi are lacking.

METHODS: We identified adults treated with olaparib or niraparib between 2015 and 2021 at a major cancer center in Boston, MA, USA. We determined the incidence of any acute kidney injury (AKI), defined as at least a 1.5-fold rise in serum creatinine from baseline in the first 12 months following PARPi initiation. We calculated the percentage of patients with any AKI and sustained AKI and adjudicated the etiologies by manual chart review. We compared trajectories in estimated glomerular filtration rate (eGFR) among PARPi-treated and carboplatin and paclitaxel-treated patients with ovarian cancer, matched by baseline eGFR.

RESULTS: Of 269 patients, 60 (22.3%) developed AKI, including 43 of 194 (22.1%) olaparib-treated patients and 17 of 75 (22.7%) niraparib-treated patients. Only 9 of 269 (3.3%) had AKI attributable to the PARPi. Of the 60 patients with AKI, 21 (35%) had sustained AKI, of whom 6 had AKI attributable to the PARPi (2.2% of the whole cohort). eGFR declined within 30 days post-PARPi initiation by 9.61 (SD = 11.017)  mL/min per 1.73 m2 but recovered by 8.39 (SD = 14.05)  mL/min per 1.73 m2 within 90 days after therapy cessation. There was no difference in eGFR at 12 months post-therapy initiation in patients receiving PARPi or controls receiving carboplatin and paclitaxel (P = .29).

CONCLUSIONS: AKI is common following PARPi initiation as is a transient decline in eGFR; however, sustained AKI directly attributable to the PARPi and long-term eGFR decline are uncommon.

Author List

Gupta S, Hanna PE, Ouyang T, Yamada KS, Sawtell R, Wang Q, Katz-Agranov N, Feghali L, Krasner CN, Bouberhan S, Castro CM, Sise ME

Author

Paul E. Hanna MD Assistant Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Acute Kidney Injury
Carboplatin
Female
Humans
Kidney
Ovarian Neoplasms
Paclitaxel
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases
Ribose